GBR-14206, a new imidazole derivative, has been evaluated against systemic infection with Candida albicans in normal and immunocompromised mice. The therapeutic effect of GBR-14206 (as a lipid emulsion) given intravenously to mice infected systemically with C. albicans was superior to that of miconazole. GBR-14206 also showed a candicidal effect in the blood stream at the therapeutic dose. In addition, GBR-14206 inhibited the hyphal growth (yeast to hyphal transformation) in Eagle's minimum essential medium and methionine synthetic medium at the respective concentrations of 0.20 and 0.05g/ml, which were approximately 3 to 7 times more active than miconazole.
Introduction
Systemic candidiasis is a significant complication of immunosuppressive disease, surgical procedure, and immunosuppressive medical therapy.
For over 25 years, amphotericin B has provided the standard treatment for systemic fungal infections. However, this drug is less than ideal in many respects, especially with regard to its extreme toxicity (most commonly, nephrotoxicity)3). In the search for alternative therapies, the azole compounds represent an important development. An intravenous preparation of miconazole had some success against systemic mycosis4,5), but its use was limited by the need to give it by continual intravenous infusion and patient discomfort, some of which may be related to the use of Cremophor EL as a solvent3).
Optimal therapy for fungal infection has not yet been defined. Although oral agents are usually most convenient, parenteral therapy may be necessary in immediately postoperative patients or in those with drug-induced malabsorption G.E. Bennett, Proc. 13th Int. Cong. Chemother. 1983, seminar 4.8/1).
GBR-14206 (z-1-2-(2,4-dichlorophenyl)-3-methyl-1-pentenyl-1H-imidazole) is a newly developed imidazole antifungal agent, which shows strong and broad spectrum activities in vitro to the same degree as the previous imidazole, miconazole7). We have recently succeeded in developing a lipid emulsion of GBR-14206, so-called lipo GBR-14206, which makes it possible to give a one shot intravenous injection in clinical application.
In this report, we present our findings on the activities of GBR-14206 compared with those of. miconazole against Candida albicans in both in vitro suppressive activity in hyphal growth and in in vivo experimental systemic infection.
Materials and Methods

Fungi
For in vivo study, C. albicans CAA-14 (clinical isolate), which was purchased from Kyoto Biseibutsu Kenkyusho, Japan was used throughout. GBR-14206 and miconazole showed the same MIC values against C. albicans CAA-14 (0.39g/ml).
For in vitro study, C. albicans IFO-1594 and CAA-14 were used. Organisms were maintained on modified Sabouraud dextrose agar slant (0.4% glucose, 0.1% polypepton, 1.5% agar) with paraffin over-laying, and fresh cultures were as needed grown on Sabouraud dextrose agar (Nissui) for 24 hr at 27C for C. albicans IFO-1594 and at 37C for C. albicans CAA-14. Compounds GBR-14206, miconazole, and ketoconazole were synthesized in the Research Laboratories of Morishita Pharmaceutical Co., Ltd..
For in vivo study, lipo GBR-14206 (0.05-0.4% GBR-14206), which was prepared by the method described previously,8) and Florid(R) F-inj (Mochida Pharmaceutical Co., Ltd.) as an intravenous preparation of miconazole were used. Laboratory animals Male mice of the ICR (Charles River) strain, 5-weeks-old and weighing 25-28g, were used for studies on systemic infection. Animals were maintained in an air-conditioned room at 20C and were allowed food and water ad libitum. Inhibitory effect on hyphal growth This experiment was performed using a microplated system with 96 wells. Saline-washed blastospores (1X102) of C. albicans CAA-14 or C. albicans IFO-1594 were inoculated in 200ul of Eagle's minimum essential medium supplemented with 10% fetal calf serum (EMEM)12) or methionine synthetic medium (MSM)10) contain serially diluted test drugs (0.00313-100ag/ml), and cultured at 37C and 60% relative humidity under 5% CO2 gas. The drugs were dissolved in dimethylsulfoxide and added to the cultures. Controls were similarly set up with an equivalent amount of the solvent (final concentration: 1.0%).
Hyphal development from yeast cells was examined microscopically at 24hr after inoculation. The inhibitory concentration of the drugs was determined by complete inhibition of hyphal growth.
Systemic infection in normal mice
Infection in normal mice was produced by injection (via the lateral tail vein) of 1X106 salinewashed blastospores of C. albi cans CAA-14, a dose generally lethal for placebo-treated animals within 15 days. Lipo GBR-14206 (dose range, 5 to 40mg/kg) or miconazole (dose range, 20 to 40 mg/kg) was administered intravenously twice daily for 3 days, starting at 1hr postinfection. Control animals received a placebo-lipid vehicle (for lipo GBR-14206) or 6% HCO 60 (hydrogenated castor oil)-saline (for miconazole). Each group consisted of 10 mice. Results were expressed as median survival days (MSD) and their percentage to control group (T/C). Systemic infection in cyclophosphamide-treated mice Animals were immunocompromised by intraperitoneal injection of cyclophosphamide (100 mg/kg; Endoxan(R), Shionogi Co., Ltd.) at 2 days before and on the day of infection. The infection was established by intravenous injection of 5X 105 blastospores of C. albi cans, and placebo-treated animals generally died within 5 days. Starting at 1 hr postinfection, animals were administered either lipo GBR-14206 in a dose ranging from 10 to 40mg/kg or miconazole in a dose ranging 40 to 60 mg/kg intravenously, twice daily for 3 days. Each group consisted of 10 mice. Systemic infection in dexamethasone-treated mice Animals were immunocompromised with a daily oral dose of dexamethasone acetate (1 mg/kg; Sigma) for 4 days, starting 2 days before infection. The infection was established by intravenous injection of 2.5X106 blastospores of C. albicans CAA-14, and placebo-treated animals generally died within 5 days. Starting at 1hr postinfection, animals were administered either lipo GBR-14206 in a dose ranging from 10 to 40 mg/kg or miconazole in a dose ranging 40 to 60 mg/kg intravenously, twice daily for 3 days. Each group consisted of 10 mice. Candicidal activity in blood stream Animals were challenged by intravenous injection of 5X106 blastospores of C. albicans CAA-14. Lipo GBR-14206 (dose range, 10 to 40mg/kg) or miconazole (dose range, 20 to 40mg/kg) was administered intravenously at 5min postinfection. At 60 and 120min postinfection, blood was collected by cardiac puncture. Efficacy was assessed by measuring the number of viable Candida cells in each blood sample. Blood samples (0.1ml) were diluted 20 fold with saline and mixed with 20ml of slightly modified Sabouraud dextrose agar (4% glucose, 1% polypepton, 1% yeast extract, 0.75% agar) containing 50ug/ml Kanamycin sulfate maintained at 4C. Agar was fixed and incubated at 37C for 48hr, then the number of colony forming units was manually counted. The effect of drug carry-over into cultures was offset by dilution.
The statistical significance of differences between the control and drug-treated groups was determined using student's t-test.
Results
Inhibitory effect on hyphal growth
In order to examine the effect of GBR-14206 on morphogenetic transformation of C. albicans, hyphal development from yeast was examined microscopically 24hr after inoculation. As shown in Table 1 , GBR-14206 blocked completely the hyphal development at 0.2ug/ml in EMEM and 0.05ug/ml in MSM, whereas miconazole required for the same effect was 0.78 and 0.39ug/ml, respectively. Thus, GBR-14206 showed a stronger activity than miconazole in the yeast to hyphal transformation, although the most remarkable activity was obtained with ketoconazole in EMEM as previously described by Cutsem12).
Systemic infection in normal mice
The protective activity of lipo GBR-14206 administered intravenously to mice which had been infected with C. albicans is shown in Fig. 1-1, 2 . Lipo GBR-14206 showed a dose-dependent prolongation of survival day at the dose of 5mg/kg up to 40mg/kg compared with that of control animals. For example, when intravenously administered at a dose of 40mg/kg, the survival rate at day 30 after infection of mice treated with lipo GBR-14206 and miconazole was 40% and 20%, respectively (data not shown). Table 2 shows the median survival day (MSD) and percentages vs. control (T/C). Lipo GBR-14206 showed superior protection to that of miconazole. No difference was observed in placebotreated controls between lipid-vehicle and 6% HCO 60-saline. Systemic infection in cyclophosphamide-treated mice Mice made neutropenic with cyclophosphamide lack approximately 90% of their circulating neutrophiles for 3 to 4 days and are more susceptible to the lethal effect of C. albicans than normal animals2).
The protective activity of lipo GBR-14206 against neutropenic mice is summarized in Table 3 . Mice without pretreatment with immunosupressive agent all survived more than 14 days (data not shown). Administration of lipo GBR-14206 improved MSD in a dose-dependent manner from 10mg/kg up to 40mg/kg. In contrast, miconazole showed no effect even at the dose of 60mg/kg. Systemic infection in dexamethasone-treated mice Results are summarized in Table 3 . Administration of lipo GBR-14206 showed a dose-dependent prolongation of MSD from 10mg/kg up to 40 mg/kg. Similar but lower effect was obtained with miconazole at a dose of 60mg/kg. Thus, lipo GBR-14206 was found to be more potent than miconazole in immunocompromised-mice infected with C. albicans. Candicidal activity in blood stream It is known that Candida cells intravenously injected into mice decrease in the blood stream within several hours and are undetectable at 24hr postinfection (data not shown). Therefore, we assessed the candicidal activity of drugs within 2 hr. Results are shown in Table 4 . There were observed 560 and 250 colony forming units/ml in the control group at 60 and 120min postinf ection, respectively. Administration of lipo GBR-14206 produced a significant reduction in number of Fig. 1-1, 2 . Healthy mice were infected intravenously with C. albicans CAA-14 (1X106 blastospores/head).
Each agent was administered intravenously twice daily for 3 days, starting at 1hr postinefection. colony forming units at 20 to 40mg/kg at 60min and at 40mg/kg at 120min postinfection. In contrast, miconazole showed no significant reduction even at a high dose (40mg/kg).
Discussion
Opportunistic pathogens, in particular C. albicans, represent an increasing threat to patients with impaired defense mechanisms and therefore there is an urgent need for better agents to combat systemic candidiasis.
Miconazole is a currently licensed imidazole derivative and its side effects are reported to be fewer than amphotericin B9). Administration of miconazole is via continual intravenous infusion with patient discomfort, which may be in part due to Cremophor EL or HCO-60 added as a solvent9). Although oral agents are usually most advantageous, parenteral therapy may also be convenient for postoperative patients or for patients with drug-induced malabsorption. In this connection, the lipid emulsion of GBR-14206 (lipo GBR-14206) has facilitated the development of an i.v. formulation of the drug suitable for use in human8).
In the present studies, lipo GBR-14206 showed We further investigated the effect of GBR-14206 on morphogenetic transformation from yeast to hyphae of C. albicans, because the clinically invasive form of C. albicans is the hyphal form6). In the present study, it was observed that GBR-14206 blocked completely the hyphal development from yeast form at the concentration of 0.2 or 0.05 pg/ml in EMEM and MSM, respectively. The concentration required to exert the same effect of miconazole was 3 to 5 fold higher than that of GBR-14206. Publishhed data confirmed the therapeutic efficacy of miconazole against candidiasis both in experimental animals1,11) and in clinical experiences4). In the present study, GBR-14206 was found superior to miconazole in treatment of systemic candidiasis in mice. Thus, GBR-14206 may be useful in therapy of human candidiasis.
